title: [Effect of fructose-1,6-diphosphete on myocardial preservation during pulmonary operations].
abstract: OBJECTIVE
  To investigate the effect of fructose-1,6-diphosphete(FDP) on myocardial preservation in pulmonary operations.
  
  
  METHODS
  One hundred and six patients undergoing selective pulmonary lobectomy or segmentectomy were randomly divided into 2 groups with 53 patients each. FDP 200 mg/kg was infused intravenously before anesthesia in the FDP group, while 5% glucose with the same volume was given instead of FDP in the control group. ECGs were monitored from before the anesthesia to 72 h after the operation;the time and type of arrhythmia were recorded. Blood samples were taken before the operation (T0), immediately after the operation(T1), at 24 h(T2),48 h(T3)and 72 h(T(4)) after the operation to determine plasma creatine kinase isoenzyme MB(CK-MB) and cardiac troponin I(cTnI) concentrations.
  
  
  RESULTS
  The incidence of arrhythmia in FDP group (35 times) was significantly lower than that in the control group(67 times). The incidence of all types of arrhythmia in the FDP group was also significantly lower than that in the control group. The concentrations of CK-MB and cTnI in the FDP group were significantly lower than those in the control group at T1, T2, T3, and T4.
  
  
  CONCLUSIONS
  FDP is effective for myocardial preservation in pulmonary operations.
authors.affiliation: Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Xiang-hui
authors.initials: XH
authors.lastname: Xu
authors.forename: Ye-tian
authors.initials: YT
authors.lastname: Chang
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Dong-mei
authors.initials: DM
authors.lastname: Zhang
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Zou
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D052279:Creatine Kinase, MB Form / Q000097:blood; D005260:Female; D005635:Fructosediphosphates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy / Q000009:adverse effects*; D019210:Troponin I / Q000097:blood*
chemical_list: D000889:Anti-Arrhythmia Agents; D005635:Fructosediphosphates; D019210:Troponin I; D052279:Creatine Kinase, MB Form; C029063:fructose-1,6-diphosphate